PCSK9 ANTAGONIST COMPOUNDS

VE6142020000136SUndetermined Publication Date: 2022-02-17MERCK SHARP & DOHME CORP
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
VE · VE
Patent Type
Designs
Current Assignee / Owner
MERCK SHARP & DOHME CORP
Filing Date
2020-08-28
Publication Date
2022-02-17
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

The compounds of formula A, or an acceptable pharmaceutical salt thereof, are disclosed: wherein A, X, R1 and R2 are as defined herein, which compounds have properties to antagonize PCSK9. Also described are the pharmaceutical formulations comprising the compounds of the formula IO, their salts, and the methods of treatment of cardiovascular diseases and conditions related to PCSK9 activity, for example, atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular diseases and cardiometabolic conditions.